IDH2 and non-small cell lung carcinoma: Due to the increasing number of NSCLC patients with IDH mutations detected by NGS and the results of a series of clinical trials involving patients with IDH mutations, mutant IDH has emerged as an ideal therapeutic target for lung cancer.